17102. Epub ahead of print. PMID: 35607817. Sörensen-Zender I, Rong S, Haller H, Schmitt R. The Therapeutic Potential of Zinc-Alpha2-Glycoprotein (AZGP1) in Fibrotic Kidney Disease. Int J Mol Sci. 2022 Jan
treatment - a systematic review and metaanalysis. Predictors of adverse events during and after therapeutic plasma exchange - a retrospective cohort study. Kontakt E-Mail schmidt.bernhard(at)mh-hannover
Institute of Health Sciences Fenja Laue Research Topic: Pan-genotypic neutralizing antibodies as a therapeutic option against Hepatitis E Virus Supervisor: Dr. Patrick Behrendt, Research Group Translational
November 2020. Jovana Markovic SERBIA Supervisor: Dr. Amar Deep Sharma, AG Cantz, OE 6817 Project: Therapeutic reprogramming for the treatment of chronic liver disesases. Final exam November 2021. Toni Luise
Schambach, Insitute of Experimental Haematology, Project: Development and validation of novel gene therapeutic approaches for correction of and protection from hearing loss Final exam June 2024 Dimyana Neufeldt
tumour microenvironment in hepatocellular carcinoma (HCC) (title: ‘Deciphering the function and therapeutic potential of innate lymphoid cells in the immune network of liver cancer to overcome resistance
magnetic stimulation (TMS)). We specialize in ECT given it is still one of the most effective therapeutic methods for the treatment of severe psychiatric conditions, such as DTD or pharmacotherapy-resistant [...] polymorphisms in cytochrome P450 enzymes (CYP) (and thus the failure to reach efficient, i.e., therapeutic drug levels) or the presence of pseudo-resistance (caused by inadequate drug intake or administration)
attempt to combine biological and technological progress with a detailed risk assessment of novel therapeutic approaches. The experimental scope of our institute ranges from investigation of basic mechanisms
rapie des Hepatozellulären Karzinoms (HCC). In der aktuell in dem wissenschaftlichen Journal „Therapeutic Advances in Medical Oncology“ publizierten Artikel “ Atezolizumab and bevacizumab in patients with
used to develop specific allosteric inhibitors of myosin isoforms with a wide range of potential therapeutic applications in the treatment of diseases, including cancer, heart failure, and malaria. Catalysis